MCF-7 cells migrate through vitronectin-coated filters in response to insulin-like growth factor I (IGF-I); migration is inhibited by the matrix metalloproteinase (MMP) inhibitor BB-94, but not by the serine proteinase inhibitor aprotinin. MMP-9 was identified in the conditioned medium of MCF-7 cells; in addition, fluorescence-activated cell sorting analysis revealed its presence on the cell surface, where MMP-9 activity was also found using a specific fluorogenic peptide. Furthermore, the messenger RNA encoding MMP-9 was detected in MCF-7 cells by PCR. The IGF-I concentration leading to maximal MCF-7 invasion produces an increase in cell surface proteolytic activity after short incubation periods. At 18 h, however, preincubation of MCF-7 cells with IGF-I produces at 18 h a dosedependent decrease in cell-associated MMP-9 activity and an increase in soluble MMP-9. MCF-7 invasion is dependent on the ␣ v ␤ 5 integrin, a vitronectin receptor. The levels of ␣ v -and ␤ 5 -subunits expressed in MCF-7 cells depend on the IGF-I concentration, which triggers an increase in both of these subunits. Based on these results, we suggest that IGF-I-induced MCF-7 cell migration is mediated by the MMP-9 activity on the cell surface and by ␣ v ␤ 5 integrin. (Endocrinology 140: [1657][1658][1659][1660][1661][1662][1663][1664] 1999) 
T UMOR CELL migration is one of the most important events contributing to tumor dissemination, and its prevention may arrest malignant evolution (1) . Insulin-like growth factor I (IGF-I) has been implicated in the migration of several cell lines in vitro and in vivo, including the estrogen receptor-positive MCF-7 breast carcinoma cell line (2) (3) (4) . IGF-I is also a mitogen for human breast cancer cells (5) , and the combination of the chemoattractant and mitogenic activities of IGF-I probably contributes to tumor survival and progression.
Tumor dissemination has been correlated with matrix metalloproteinases (MMP) due to their proteolytic activity on extracellular matrix proteins (6) . More recently, MMP have been implicated in the release of the soluble form of several growth factors (7) , and interestingly, several IGF-binding proteins have been described as MMP substrates (8 -10) . Together, these data enlarge the relevance of this proteinase family on sustaining an invasive phenotype. Among its members, MMP-9 exhibits a widespread expression in a variety of human cancers, suggesting its involvement in human tumor dissemination (11) . Direct evidence of its role in tumor progression is derived from transfection experiments in which the MMP-9 gene in nonmetastatic cells endowed them with the ability to metastasize (12) .
Besides the requirement of proteolysis, adhesion to the extracellular matrix is necessary for tumor invasion (13) . Integrin molecules belong to the largest family of extracellular matrix (ECM) adhesion receptors and have been implicated in several processes, including cell migration, invasion, and metastasis (14, 15) . The link between integrins and MMP comes from experimental evidence such as the colocalization of the integrin ␣ v ␤ 3 and MMP-2 (16) and the positive regulation of MMP-1 expression by the integrin ␣ 2 ␤ 1 (17) . Furthermore, integrin function is a requirement for IGF-I-mediated chemotaxis; in MCF-7 cells, migration through vitronectin and type IV collagen is dependent on ␣ v ␤ 5 and ␣ 2 ␤ 1 , respectively, and in smooth muscle cells, ligand occupancy of ␣ v ␤ 3 modulates the migration process (2, 3) . The dissemination of several malignant tumor cells is also dependent on the cooperation between ␣ v ␤ 5 and IGF-I (4).
Although IGF-I-triggered migration of MCF-7 has been previously reported (3) , the mechanism mediating the MCF-7 migratory response to IGF-I through the ECM component vitronectin has not yet been elucidated. Here we have identified MMP-9 and its proteolytic activity on the MCF-7 cell surface; we describe the IGF-I-induced changes in MMP-9 and the vitronectin receptor ␣ v ␤ 5 and their correlation with the migration response.
FCS, penicillin, streptomycin, l-glutamine, and sodium pyruvate. The HT-1080 human fibrosarcoma cell line (American Type Culture Collection) was cultured in the same medium, which was replaced by serumfree medium with 0.1% BSA and the phorbol ester phorbol 12-myristate 13-acetate (PMA; 100 ng/ml) for 1 day to obtain conditioned medium. Recombinant human IGF-I was provided by Pharmacia & Upjohn, Inc. (Stockholm, Sweden). Vitronectin was purchased from Collaborative Biomedical (Bedford, MA). Transwell chambers (pore size, 8 m) were obtained from Corning Costar (Cambridge, MA). Batimastat (BB-94) (18) was provided by Dr. F. Colotta (Pharmacia & Upjohn, Inc., Milan, Italy); aprotinin and PMA were obtained from Sigma Chemical Co. (St. Louis, MO). The monoclonal antibody (mAb) anti-IGF-I BB9E10 has been previously described (19) . Anti-IGF type 1 receptor (IGF-1R; ␣-IR3), anti-MMP-9 (Ab-1), and anti-MMP-2 (Ab-3) mAb were purchased from Oncogene (Cambridge, MA). The polyclonal anti-MMP-9 antibody (Ab), obtained by immunization with a synthetic peptide (amino acids 422-434), was purchased from Research Genetics, Inc. (Huntsville, AL). Anti-␣ v (K267) is a polyclonal Ab obtained by immunization with a synthetic peptide (amino acids 372-385), and anti-␣ v (6D1) mAb was obtained by immunizing with purified human placenta integrin ␣ v ␤ 5 ; both were produced in our laboratory. The anti-␤ 5 polyclonal Ab and anti-␣ v ␤ 5 (p1F6) mAb were purchased from Boehringer Ingelheim (Heidelberg, Germany), the anti-␤1 (DF5) mAb was obtained from Chemicon (Temecula, CA), and the anti-␣2 mAb (p1E6) was obtained from Life Technologies (Paisley, Scotland, UK).
Migration assays
MCF-7 cells (10 5 ) were trypsinized and resuspended in serum-free DMEM with 0.01% BSA, then seeded in the upper chamber of vitronectin-coated transwells (5 g/ml in PBS, 18 h at room temperature). The lower chambers were loaded with DMEM-BSA, with or without IGF-I. In some assays, cells were preincubated with Abs or inhibitors for 30 min at room temperature before seeding in the transwell. Cells were incubated for 18 h at 37 C in 5% CO 2 . The chamber was disassembled, and cells on the upper surface were removed. Filters were stained, and cell numbers were calculated as previously described (3).
MMP activity measurement
Cell surface MMP activity was measured using a modification of previously described methods (20, 21) . Briefly, 5 ϫ 10 4 cells resuspended in complete medium were seeded in 96-well microtiter plates (Nunc, Roskilde, Denmark). Cells were washed three times with HBSS (Life Technologies), and the fluorogenic peptide Dnp-Pro-␤-cyclohexyl-AlaGly-Cys(Me)-His-Ala-Lys-(N-Me-Abz)-NH 2 (Bachem, Bubendorf, Switzerland) was added in HBSS containing 0.01% NaN 3 . Plates were incubated at 37 C, and at the indicated time the increment in fluorescence was measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm with a Cytofluor microplate reader (Millipore Corp., Bedford, MA). When IGF-I was assayed, cells were starved for 6 h in serum-free medium and incubated with or without IGF-I for the time indicated. Medium was then removed, and after washing with HBSS, proteolytic activity was measured. When inhibitors were tested, they were preincubated for 30 min before the addition of the fluorogenic substrate. Fluorescence was normalized by cell staining with crystal violet (Sigma Chemical Co.). Zymograms were performed as previously described (20) in 10% SDS-polyacrylamide gels containing gelatin (1 mg/ml).
Fluorescence-activated cell sorting (FACS) analysis
MCF-7 cells were detached, washed with ice-cold PBS, and resuspended at 10 6 cells/ml in PBS with 0.5% BSA and 0.01% NaN 3 . Anti-MMP-9, anti-MMP-2, or anti-␣ v ␤ 5 mAb were added, followed by a fluorescein isothiocyanate-labeled goat antimouse IgG (Southern Biotechnology Associates, Birmingham, AL). Cell-associated fluorescence was visualized in an EPICS XL flow cytometer (Beckman Coulter, Inc., Hialeah, FL).
PCR analysis
First strand complementary DNA (cDNA) was prepared from MCF-7-isolated messenger RNA and HT1080 total RNA. Oligonucleotide primers for PCR amplification of gelatinase B were synthesized as previously described (22) , and each cycle consisted of denaturation at 94 C, annealing at 55 C, and elongation at 72 C for 30 sec in each step after 1 min at 94 C in the first cycle. The primer sequences for PCR amplification of GAPDH were as follows: sense primer, 5Ј-TCCTGCACCACCAAC TGCTTA-3Ј; and antisense primer, 5Ј-ACCACCCTGTTGCTGTAGCC-3Ј. Each cycle consisted of denaturation at 94 C and annealing at 57 C for 30 sec in each step and elongation at 72 C for 1 min after 1 min at 94 C in the first cycle.
Western blot analysis
Conditioned medium samples were electrophoresed on 10% SDSpolyacrylamide gels under reducing conditions, electroblotted, and blocked with 5% (wt/vol) nonfat milk in PBS-Tween-20 (0.1%, vol/vol). The filter was incubated with an IgG fraction of the rabbit anti-MMP-9 serum, followed by a peroxidase-conjugated goat antirabbit Ig (DAKO Corp. A/S, Glostrup, Denmark). Reactions were developed using the ECL system (Amersham, Aylesbury, UK). Cell lysates were obtained by incubating monolayer cells in lysis buffer containing 1% Triton X-100, 50 mm Tris (pH 7.5), and 300 mm NaCl at 4 C for 15 min. After detaching cells by scraping, insoluble material was removed by centrifugation. To detect integrin subunits, samples were electrophoresed on 8% SDSpolyacrylamide gels under nonreducing conditions, then processed as described above.
Immunoprecipitation of biotin-labeled integrin
Cells were grown to 80% confluence and labeled with Sulfo-NHS-LC-Biotin (Pierce Chemical Co., Rockford, IL) following the manufacturer's instructions. Cell lysates were obtained as previously described (23) and were immunoprecipitated with mAb anti-␣ v or anti-␣ v ␤ 5 (4 C, overnight), followed by agarose-conjugated goat antimouse IgG. The immunoprecipitated proteins were separated on 10% SDS-polyacrylamide gels under reducing conditions, and blots were developed using peroxidase-labeled streptavidin (Amersham) followed by enhanced chemiluminescence.
Adhesion assay
Vitronectin-coated 96-well microtiter plates (1 g/ml in PBS, overnight at 4 C) were blocked with 5% BSA in PBS for 3 h at 37 C. MCF-7 cells (3 ϫ 10 5 ) in DMEM-BSA were preincubated with anti-␣ v ␤ 5 and anti-␣ 2 mAb for 30 min and seeded. After a 2-h incubation, plates were washed three times with DMEM-BSA, and adherent cells were stained with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (Sigma Chemical Co.) (24) .
Statistical analysis
All experiments were repeated two or three times. The mean and sd of triplicate points from one or two experiments are shown. Zymographic data and the corresponding densitometry quantitation are presented from a representative experiment. The significant differences between group values were analyzed using the Kruskal-Wallis test, and the Mann-Whitney test was used to compare paired values.
Results

MCF-7 cell migration in response to IGF-I is inhibited by the MMP inhibitor BB-94
When seeded on vitronectin-coated Transwell chambers, MCF-7 cells migrate in response to IGF-I (3). Migration observed at 18-h incubation at an IGF-I concentration of 1 ng/ml was considered maximal; migration decreases at higher IGF-I concentrations (up to 1 g/ml; Fig. 1A ). IGF-I-mediated MCF-7 cell migration is inhibited by anti-IGF-I mAb (data not shown) as well as by anti-IGF-1R mAb, as previously described (3) . This migration response to IGF-I is independent of de novo protein synthesis, as cycloheximide has no effect on this assay (data not shown).
To identify the protease responsible for MCF-7 migration, we tested the effect of proteinase inhibitors, several of which show an effect on IGF-I-triggered MCF-7 migration. MCF-7 cell migration in response to IGF-I (1 ng/ml) was inhibited up to 70% by the MMP inhibitor BB-94, whereas only a nonsignificant 10% inhibition was observed with the serine proteinase inhibitor aprotinin (Fig. 1B) . We thus conclude that IGF-I-triggered MCF-7 cell migration is specific and dose dependent, is mediated through the IGF-1R, and involves an MMP.
MMP-9 activity is anchored to the MCF-7 cell surface
MMP activity is usually analyzed in cell culture-conditioned medium, as most MMP family members are secreted proteases (6) . To characterize the MMP involved in MCF-7 migration, we therefore analyzed MCF-7 cell-conditioned medium by gelatin zymography, using HT-1080-conditioned medium as a control (25) . MCF-7-conditioned medium shows gelatinolytic activity ( Fig. 2A, upper panel, lane 3 ) coincident with the MMP-9 induced in the HT-1080 medium after PMA treatment ( Fig. 2A, upper panel, lanes 1-2) . Although the MMP-9 detected is the 92-kDa latent enzyme form (25) , it is activated by the denaturation-renaturation process in the gel, allowing analysis of its activity (20) . To confirm the identity of this gelatinolytic activity as MMP-9, Western blot analysis was performed with a polyclonal anti-MMP-9 Ab. A specific band was detected in MCF-7-conditioned medium that coincides with the mol wt found in PMA-induced HT-1080 cell-conditioned medium and absent in the medium from untreated HT-1080 cells ( Fig. 2A, lower  panel) .
Although MMP-9 is a secreted protease (11), the localization of proteases on the cell surface appears to be important in tumor invasion (26) . To determine whether MMP-9 activity is localized on the MCF-7 cell surface, we employed a fluorogenic MMP substrate specific for MMP-9 (27); MMP-1, the other protease with activity on this substrate, is not expressed in MCF-7 cells (28) . The fluorogenic peptide increases its fluorescence upon cleavage; this increment thus reflects proteolytic activity. Cells were seeded in vitronectincoated wells and incubated in complete medium for 18 h; medium was then removed to discard the possible MMP activity present in the conditioned medium. After substrate addition, cell surface-associated fluorescence was measured at various time intervals. A linear increase in fluorescence (r 2 ϭ 0.99; P Ͻ 0.001) was observed with incubation times of up to 6 h (Fig. 2B ). This activity is independent of the presence of vitronectin (data not shown). BB-94 inhibited this proteolytic activity (Fig. 2C) , with 80% inhibition after 1 h of incubation in the presence of the substrate. Less than 20% inhibition of the proteolytic activity was observed when aprotinin was included in the assay (Fig. 2C) .
To further identify this cell-bound MMP activity as that of MMP-9, FACS analysis was performed using MMP-9-specific mAb and MMP-2 as a negative control. Incubation of MCF-7 with the anti-MMP-9 Ab promoted a cell-associated shift in fluorescence intensity compared with that observed using anti-MMP-2 or the second Ab alone (Fig. 2D) . Finally, using MMP-9-specific primers, we detected messenger RNA encoding MMP-9 in MCF-7 cells (Fig. 2E, lane 3) , with PMAtreated HT-1080 cells as a control (Fig. 2E, lane 1) . We conclude that MMP-9 is expressed by MCF-7 cells, is located on the cell surface, and is found in the conditioned medium, and that its activity is at least in part responsible for MCF-7 cell-associated protease activity. 
IGF-I triggers changes in MMP-9 activity in MCF-7 cells
MMP-9 is present in MCF-7 cell-conditioned medium, and its activity is associated with the cell surface in the absence of IGF-I treatment. As MCF-7 cells migrate through vitronectin only in the presence of IGF-I, we analyzed the possible effect of IGF-I treatment on MMP-9 activity, measuring both cell surface-associated proteolytic activity and MMP-9 in the conditioned medium. A dose-dependent decrease (r 2 ϭ 0.71; P Ͻ 0.05) in cell surface-associated MMP-9 activity was observed when starved cells were treated with IGF-I for 18 h (Fig. 3A) , whereas a 2.5-fold increase in the latent soluble form of MMP-9 was detected in the conditioned medium (Fig. 3B) . This treatment does not activate the latent MMP-9 form, as we observed no lower mol wt bands corresponding to activated forms (29) . MMP-9 enhancement in the conditioned medium is vitronectin independent, as also found for the MMP-9 membrane-associated activity (data not shown). The MMP-9 in the conditioned medium appears to be independent of MCF-7 migration, as this zymogen form is not activated by IGF-I treatment.
These results show that after 18-h preincubation, cell surface-associated proteolytic activity is maximal in the absence of IGF-I, in contrast to the effect of IGF-I at any dose employed. MCF-7 cells migrate only in response to IGF-I, however, reaching a maximum at 1 ng/ml (Fig. 1A) . To further analyze the possible correlation between proteolytic activity and invasion in MCF-7 cells, we performed a time-course experiment with cells untreated or IGF-I treated, and measured cell surface proteolytic activity. Although a slight increase in this activity is detected in unstimulated cells, IGF-I addition (1 ng/ml) produced a significant increase in proteolytic activity, with a maximum value after 3-4 h of preincubation (Fig. 4) . After 18 h of incubation, there was a decrease in cell membraneassociated proteolytic activity, similar to that observed in the dose-response experiment (Fig. 3A) . This early in- crease in proteolytic activity in response to IGF-I, therefore, correlates with MCF-7 cell invasion.
IGF-I treatment increases both subunits of the ␣ v ␤ 5 integrin
IGF-I-triggered migration of MCF-7 cells through vitronectin is dependent on the integrin ␣ v ␤ 5 vitronectin receptor in this cell line (3) . An anti-␣ v ␤ 5 mAb specifically blocks MCF-7 cell adhesion to vitronectin (data not shown) and inhibits migration, as previously shown (3) . To explore the effect of IGF-I treatment on ␣ v ␤ 5 , MCF-7 cells were incubated with IGF-I, and the cell lysates were analyzed in Western blot. When IGF-I was used at 1 ng/ml, neither ␣ v -nor ␤ 5 -subunit levels changed with respect to those in untreated cells; an increase in both subunits was found, however, when cells were incubated with IGF-I at higher doses (100 and 1000 ng/ml; Fig. 5A ). The ␤ 1 integrin subunit remained unchanged at any IGF-I concentration employed (Fig. 5A) . To ascertain whether the integrin ␣ v ␤ 5 levels in total extracts can be correlated with their presence on the MCF-7 cell surface, we performed immunoprecipitation experiments with biotinylated extracts. Starved cells were untreated or treated with IGF-I (1 ng/ml) overnight and subsequently biotinylated. Biotinylated extracts were immunoprecipitated with anti-␣ v , anti-␣ v ␤ 5 , or an irrelevant isotype-matched Ab as a control. Although the band corresponding to ␣ v was quite faint, both ␣ v -and ␤ 5 -subunits were immunoprecipitated by anti-␣ v and anti-␣ v ␤ 5 (Fig. 5B) . The band intensity was similar in both extracts (Fig. 5B) , confirming the result observed in Western blot analysis of total extracts. No changes in ␣ v ␤ 5 staining were detected by FACS analysis in MCF-7 cells under the same incubation conditions (data not shown). In this system, therefore, the IGF-I concentration leading to maximal migration (1 ng/ml) does not alter ␣ v ␤ 5 levels; higher IGF-I doses, associated with a lack of MCF-7 migration, produce an increase in ␣ v ␤ 5 integrin levels.
Discussion
As proteinases have been implicated in cell motility and invasion (30), they were analyzed here to elucidate the mechanism by which MCF-7 cells migrate through vitronectin in response to IGF-I. Both serine proteases and MMPs have been correlated with the invasive phenotype (26); we thus employed inhibitors specific for these proteinases. MCF-7 migration in response to IGF-I was abolished using the MMP inhibitor BB-94, whereas only slight inhibition was produced by the serine protease inhibitor aprotinin. We thus focused on the role of MMPs in MCF-7 cell migration.
Most MMPs described to date are soluble enzymes se- creted as proenzymes, processed to generate their active forms (31), but cell surface-associated MMP activity has recently been described (32, 33) . Membrane-type MMP have been identified on fibroblast cells of human carcinomas (28, 33) , and in addition, the soluble MMP gelatinase A exhibits cell surface association in invasive cells (16) . We have described the presence of MMP-9 in the conditioned medium of MCF-7 cells, as analyzed by Western blot and gelatin zymography. We have also detected MMP-9 on the MCF-7 cell surface; using an MMP-specific substrate, we observed activity in intact MCF-7 cells, and as expected for an MMP, this activity was inhibited by BB-94, but not by aprotinin. Furthermore, an anti-MMP-9 mAb specifically stains MCF-7 cells. These results led us to conclude that MMP-9 is expressed by MCF-7 cells and is located on the cell surface as well as in the conditioned medium. Although both MMP-2 and MMP-9 gelatinases have been found on the cell surface (16, 32, 34 -36) , this is, to our knowledge, the first description of MMP-9 activity on the cell membrane. At least two events must take place in or near the cell surface to allow the appearance of MMP-9 activity, the binding of the newly synthesized proform, followed by its activation. High affinity binding of pro-MMP-9 to the collagen type IV ␣2(IV) chain has been described in MCF10A cells (34) . This binding does not, however, result in zymogen activation, which, in turn, has been associated with components of the urokinase-plasmin system (35, 36) . In our experimental system, we found the inactive proform in the conditioned medium and detectable MMP-9 activity only at the cell membrane level. Our data, therefore, support the idea that although inactive MMP-9 binds to ECM components, an activation step is required at the cell membrane. The mechanism of this activation in MCF-7 requires further study, although the fact that aprotinin does not block MCF-7 invasion suggests that the plasmin system is not involved. Our data further support the hypothesis of protease focalization on the cell membrane as a possible mechanism to increase proteolytic activity, producing more efficient invasion, as previously suggested (26, 30, 37) . Long term IGF-I treatment of MCF-7 cells produces a dose-dependent decrease in MMP-9 activity on the cell surface and an increment in MMP-9 in the conditioned medium. When cycloheximide was included in the invasion assay, the results were unchanged; de novo protein synthesis is therefore not required for MCF-7 cell migration in response to IGF-I. From these observations, we hypothesize that IGF-I promotes a redistribution of an MMP-9 pool between the cell surface and the medium. Only the MMP-9 proform has been detected in the MCF-7-conditioned medium; therefore, MMP-9 in the MCF-7-conditioned medium does not appear to correlate with the invasive phenotype. A cell surface-associated protease activity would thus seem to be more relevant than a soluble form in the enhancement of a migration response. The maximal migration rate was observed with 1 ng/ml IGF-I, a dose leading to a significant increase in MCF-7 cell surface-associated MMP-9 activity. The decrease detected after 18-h incubation could be explained by the autoproteolytic activity of the protease, leading to its inactivation. In the absence of exogenous IGF-I, the increase in proteolytic activity is gradual, probably due to the autocrine IGF-I produced (38) , and the concomitant inactivation must be delayed.
Cell movement can be observed as a continuous interplay between adhesion and de-adhesion events (39, 40) . Adhesion receptors such as integrins are needed to promote cellular invasion (41) . Indeed, our results indicate that IGF-I-triggered MCF-7 chemotaxis requires cell adhesion to a specific ECM substrate through integrins, as blocking of ␣ v ␤ 5 integrin binding with an antagonist Ab results in the inhibition of the IGF-I-induced invasive response on vitronectin. These data are similar to those reported previously (3) . Although cell attachment to the proper ECM substrate is required for migration, it is not sufficient in itself, as MCF-7 does not invade through vitronectin in the absence of this chemoattractant. It could thus be hypothesized that some cooperation should exist between integrins and IGF-I, either by modification of the integrin levels or by affecting the integrin-mediated signaling pathways. IGF-I treatment of MCF-7 cells at the dose that induces maximum invasion does not promote any change in the ␣ v ␤ 5 integrin levels. These data concur with results reported previously for several cell lines in which cell migration is regulated by mechanisms independent of changes in the integrin levels (4, 42, 43) . On the other hand, IGF-I at high doses produces an increase in ␣ v ␤ 5 integrin levels that parallels with decreased migration. An excess of cell adhesion to the underlying ECM could therefore be negative for cell migration, as described for CHO cells, in which integrin accumulation in the cell membrane diminishes cell migration speed (40) .
Adhesion to the ECM and proteolysis of ECM components are necessary for tumor invasion (16, 17, 44) . A functional link between adhesion and proteolysis has been shown in melanoma cells, in which MMP-2 is induced and cellular invasion increased after vitronectin ligation to the integrin ␣ v ␤ 3 (45) . In our system, adhesion and proteolysis are effected by the integrin ␣ v ␤ 5 and MMP-9, respectively. Precise regulation of these two components must take place to achieve the invasive phenotype. MMP-9 must be localized and active on the cell surface, where membrane association may affect its activity, as has also been suggested for MMP-2 (45) . The levels of integrin and its activated state in response to IGF-I treatment must modify cell spreading, adhesion, and detachment, which could, in turn, affect MMP activity, leading to an invasive phenotype.
In conclusion, in addition to the role of integrins in cell migration, we highlight the importance of cell surface-anchored MMP-9 activity in mediating IGF-I chemoattractant activity. This finding emphasizes cell surface proteases as suitable targets in the prevention of cell dissemination, particularly in the case of tumor metastasis.
